Abstract
Over the last decades, the evaluation of potential surrogate endpoints in clinical trials has steadily been growing in importance, not only thanks to the availability of ever more potential markers and surrogate endpoints, also because more methodological development has become available. While early work has been devoted, to a large extent, to Gaussian, binary, and longitudinal endpoints, the case of time-to-event endpoints is in need of careful scrutiny as well, owing to the strong presence of such endpoints in oncology and beyond. While work had been done in the past, it was often cumbersome to use such tools in practice, because of the need for fitting copula or frailty models that were further embedded in a hierarchical or two-stage modeling approach. In this paper, we present a methodologically elegant and easy-to-use approach based on information theory. We resolve essential issues, including the quantification of “surrogacy” based on such an approach. Our results are put to the test in a simulation study and are applied to data from clinical trials in oncology. The methodology has been implemented in R.
Similar content being viewed by others
References
Alonso A, Molenberghs G (2007) Surrogate marker evaluation from an information theory perspective. Biometrics 63: 180–186
Alonso A, Molenberghs G (2008) Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Stat Methods Med Res 17: 497–504
Alonso A, Molenberghs G, Burzykowski T, Renard D, Geys H, Shkedy Z, Tibaldi F, Cortiñas J, Buyse M (2004) Prentice’s approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 60: 724–728
Alonso A, Molenberghs G, Geys H, Buyse M (2005) A unifying approach for surrogate marker validation based on Prentice’s criteria. Stat Med 25: 205–211
Alonso A, Geys H, Molenberghs G (2006) A unifying approach for surrogate marker validation based on Prentices criteria. Stat Med 25: 205–221
Boltzmannn L (1877) Über die Beziehung zwischen dem zweiten Hauptsatze der mechanischen Wärmetheorie und der Wahrscheinlichkeitsrechnung respecktive den Sätzen über das Wärmegleichgewicht (On the relationship between the second law of the mechanical theory of heat and the probability calculus). Wiener Berichte 2: 373–435
Burzykowski T, Molenberghs G, Buyse M, Renard D, Geys H (2001) Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. Appl Stat 50: 405–422
Burzykowski T, Molenberghs G, Buyse M (2005) The Evaluation of surrogate endpoints. Springer, New York
Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1: 49–67
Cardiac Arrhythmia Suppression Trial (CAST) Investigators: (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction. N Engl J Med 321: 406–412
Clayton DG (1978) A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 65: 41–151
Cover T, Tomas J (1991) Elements of information theory. Wiley, New York
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34: 187–220
Cox DR (1975) Partial likelihood. Biometrika 62: 269–276
Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
Daniels MJ, Hughes MD (1997) Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16: 1515–1527
DeGruttola V, Fleming TR, Lin DY, Coombs R (1997) Validating surrogate markers—are we being naive?. J Infect Dis 175: 237–246
Duchateau L, Janssen P (2007) The Frailty Model. Springer, New York
Dunn N, Mann RD (1999) Prescription-event and other forms of epidemiological monitoring of side-effects in the UK. Clin Exp Allergy 29: 217–239
Fisher R (1925) Theory of statistical estimation. Proc Camb Philos Soc 22: 700–725
Fleming TR, DeMets DL (1996) Surrogate endpoints in clinical trials: are we being misled?. Ann Intern Med 125: 605–613
Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167–178
Hartley R (1928) Transmission of information. Bell Syst Tech J 7: 535–563
Henderson R, Diggle P, Dobson A (2000) Joint modelling of longitudinal measurements and event time data. Biostatistics 1: 465–480
Hougaard P (2000) Analysis of multivariate survival data. Springer, New York
Kalbfleisch J, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kent J (1983) Information gain and a general measure of correlation. Biometrika 70: 163–173
Kent J (1986) The underlying structure of nonnested hypothesis tests. Biometrika 73: 333–344
Kent J, O’Quigley J (1988) Measure of dependence for censored survival data. Biometrika 75: 525–534
Kullback S, Leibler R (1951) On information and sufficiency. Ann Math Stat 22: 79–86
Lagakos SW, Hoth DF (1992) Surrogate markers in AIDS: where are we? Where are we going?. Ann Intern Med 116: 599–601
Lesko LJ, Atkinson AJ (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41: 347–366
Molenberghs G, Kenward MG (2007) Missing data in clinical studies. Wiley, Chichester
Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M (2008) The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. J Stat Plan Inference 138: 432–449
Nelson RG (1999) An introduction to Copulas. Lecture Notes in Statistics, vol 139. Springer, New York
Nyquist H (1924) Certain factors affecting telegraph speed. Bell Syst Tech J 3: 324–346
O’Quigley J (2008) Proportional hazards regression. Springer, New York
O’Quigley J, Flandre P (2006) Quantification of the Prentice criteria for surrogate endpoints. Biometrics 64: 297–300
O’Quigley J, Xu R, Stare J (2005) Explained randomness in proportional hazards models. Stat Med 24: 479–489
Prentice RL (1989) Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med 8: 431–440
Pryseley A, Tilahun A, Alonso A, Molenberghs G (2007) Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints. Clin Trials 4: 587–597
Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M (2002) Validation of surrogate endpoints in randomized trials with discrete outcomes. Biom J 30: 1–15
Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M, Vangeneugden T, Bijnens L (2003) Validation of a longitudinally measured surrogate marker for a time-to-event endpoint. Appl Stat 30: 235–247
Sargent DJ, Wieand HJ, Haller DG, Gray R (2003) Disease-free survival versus overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trails. J Clin Oncol 23: 8664–8670
Schemper M, Stare J (1996) Explained variation in survival analysis. Stat Med 15: 1999–2012
Shannon C (1948) A mathematical theory of communication. Bell Syst Tech J 27:379–423 and 623–656
Szilárd L (1929) On the decrease in entropy in a thermodynamic system by the intervention of intelligent beings. Z Phys 53: 840–856
Tibaldi FS, Cortiñas Abrahantes J, Molenberghs G, Renard D, Burzykowski T, Buyse M, Parmar M, Stijnen T, Wolfinger R (2003) Simplified hierarchical linear models for the evaluation of surrogate endpoints. J Stat Comput Simul 73: 643–658
Tilahun A, Assam P, Alonso A, Molenberghs G (2007) Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS. Comput Stat Data Anal 51: 4152–4163
Xu R, O’Quigley J (1999) A measure of dependence for proportional hazards models. J Nonparametr Stat 12: 83–107
Xu R, O’Quigley J (2000) Proportional hazards estimate of the conditional survival function. J R Stat Soc B 62: 667–680
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
The Below is the Electronic Supplementary Material.
Rights and permissions
About this article
Cite this article
Pryseley, A., Tilahun, A., Alonso, A. et al. An information-theoretic approach to surrogate-marker evaluation with failure time endpoints. Lifetime Data Anal 17, 195–214 (2011). https://doi.org/10.1007/s10985-010-9185-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10985-010-9185-6